抑制LCN2可以通过促进铁化抑制NSCLC的发展
Zhongjun Pan1, Ben Li2, Peng Lu2
1Department of Cardiovascular Surgery, The First Afiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu Province, China; The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang 212300, Jiangsu Province, China.
Gene
|November 24, 2023
概括
减少利波卡林-2 (LCN2) 诱导铁,抑制非小细胞肺癌 (NSCLC) 的进展. 这项研究确定LCN2是NSCLC生长和迁移的关键驱动因素,提供了潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 细胞死亡研究 细胞死亡研究
- 分子生物学分子生物学
背景情况:
- 瘤进展与ferroptosis有关,ferroptosis是一种受调节的细胞死亡途径.
- 在非小细胞肺癌 (NSCLC) 中铁亡的特定触发因素尚不清楚.
研究的目的:
- 调查Lipocalin-2 (LCN2) 在NSCLC内的铁化中的作用.
- 确定LCN2调制是否影响NSCLC细胞行为和铁亡.
主要方法:
- 对NSCLC样本的转录组测序以识别差异表达的基因.
- 使用NSCLC细胞系 (BEAS-2B,A549,H1299,PC-9,H1975) 进行验证,并使用西部斑,CCK8,EDU,scratch,Transwell和铁化试验.
- 使用小鼠瘤异种移植模型进行体内评估.
主要成果:
- 在NSCLC患者和细胞中,LCN2被上调,与预后不佳相关.
- 抑制LCN2促进了铁亡,抑制了NSCLC的增殖和迁移.
- 铁素-1 (Fer-1) 逆转了LCN2的作用,表明LCN2在ferroptosis调节中的关键作用.
结论:
- 降低LCN2表达有效诱导NSCLC中的铁亡.
- 抑制LCN2是一种有希望的策略,可以阻碍NSCLC的生长和进展.
更多相关视频
10:16SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
Published on: January 6, 2017
7.4K
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
7.6K
相关概念视频
01:16Necrosis
4.5K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.5K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K